NL-GBM, 1996 - Google Patents
New subgroup of primary IgA nephritis with thin glomerular basement membrane (GBM): syndrome or associationNL-GBM, 1996
View PDF- Document ID
- 16194384986675786511
- Author
- NL-GBM T
- Publication year
- Publication venue
- Nephrol Dial Transplant
External Links
Snippet
Sir, IgA nephritis (IgA-N) is the most common form of glomerulonephritis and occurs mostly in males. For 2 years, we have prospectively measured glomerular basement membrane (GBM) thickness in glomerular diseases, by a classic electronmicroscopy technique. The …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL-GBM | New subgroup of primary IgA nephritis with thin glomerular basement membrane (GBM): syndrome or association | |
| Rodrfguez-Puyol | The aging kidney | |
| NL8802634A (en) | THERAPEUTIC PREPARATIONS. | |
| JP2002521435A (en) | Methods for treating conditions modulated by lactosylceramide | |
| KR20200128676A (en) | Use of Migalastat for the treatment of Fabry disease in pregnant patients | |
| CN115279372A (en) | Methods of treating erythropoietic protoporphyrinopathy, X-linked protoporphyrinopathy or congenital erythropoietic porphyrias with glycine transporter inhibitors | |
| JP2021006548A (en) | Agent for treating or preventing presbyopia containing ursodeoxycholic acid | |
| JP2025183335A (en) | Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic nephropathy | |
| Kerstens et al. | Lack of relationship between 11β‐hydroxysteroid dehydrogenase setpoint and insulin sensitivity in the basal state and after 24h of insulin infusion in healthy subjects and type 2 diabetic patients | |
| Gibson et al. | Vigabatrin therapy in patient with succinic semialdehyde dehydrogenase deficiency | |
| Giudicelli et al. | Are the metabolic characteristics of congenital intraspinal lipoma cells identical to, or different from normal adipocytes? | |
| Levens et al. | Renal actions of a new adenosine agonist, CGS 21680A selective for the A2 receptor. | |
| EP1341532B1 (en) | Use of pyridoxamine for the treatment and inhibition of obesity-related complications | |
| US20110105574A1 (en) | Pai-1 expression and activity inhibitors for the treatment of ocular disorders | |
| JP2016503794A (en) | Methods for treatment of disease | |
| Khoshsorour et al. | Bilateral inguinal hernia associated with Alport's syndrome: report of the first case | |
| Arumanayagam et al. | Platelet sodium pump and sodium potassium cotransport activity in nonpregnant, normotensive, and hypertensive pregnant women | |
| WO2020084113A1 (en) | Sildenafil for use in the treatment of osteoarthritis in horses | |
| Wu et al. | Human vasoactive hormone adrenomedullin and its binding protein rescue experimental animals from shock | |
| Bruce et al. | Enhanced endothelium‐dependent vasodilator responses in patients with systemic vasculitis | |
| CN110809468A (en) | Method of inducing chondrogenesis | |
| Iwasaki et al. | Impaired parathyroid hormone response to hypocalermic stimuli in a patient with hypomagnesemic hypocalcemia | |
| Lane | Long-term furosemide treatment in the normal rat: dissociation of glomerular hypertrophy and glomerulosclerosis | |
| JP2002500170A (en) | Pharmaceutical composition comprising thiram | |
| Thompson et al. | Dihydropyridine receptor blockers and skeletal muscle metabolism |